KTKamoltip Thungrat

Kamoltip Thungrat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kamoltip Thungrat has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Assessment of lipemia interference on phenobarbital quantification using particle-enhanced turbidimetric inhibition immunoassay with Dimension clinical chemistry system and comparison to high-performance liquid chromatography

    by Kamoltip Thungrat, Phabpim Thumarat, Alex L. Jenkins, Crisanta Cruz-Espindola

    Phenobarbital, an anti-seizure medication with a narrow therapeutic window, requires therapeutic drug monitoring (TDM) for safe and effective use. Lipemia is a well-known interferent in turbidimetric immunoassays, yet its impact on phenobarbital quantification compared with high-performance liquid chromatography (HPLC) has not been fully characterized. We evaluated the effect of lipemia on phenobarbital measurement using a particle-enhanced turbidimetric inhibition immunoassay (PETINIA; Dimension Xpand Plus clinical chemistry system, Siemens) versus HPLC. Simulated lipemic plasma was prepared by spiking normal canine plasma with lipid emulsion to achieve predefined lipemia indices. Naturally lipemic TDM samples (index ≥ 4; n = 40) and non-lipemic controls (index ≤ 3, n = 40) were also analyzed. Phenobarbital concentrations were compared before and after lipid reduction by double microcentrifugation using both methods. HPLC performance was stable across all lipemia indices, with consistent retention times (5.0 min), accuracy and precision within acceptance limits, and high linearity ( R ² > 0.999). In contrast, PETINIA had a significant positive bias in lipemic samples, with median bias increasing from 9.1% at index 1 to 100% at index 6. Bias was significantly higher in naturally lipemic samples (median: 74.5%) compared with non‑lipemic controls (1.2%; p < 0.001). PETINIA and HPLC had strong agreement in non-lipemic samples (Passing–Bablok regression, r = 0.99), but poor agreement and proportional positive bias in lipemic samples ( r = 0.16; slope CI [1.01, 1.89]). PETINIA overestimated phenobarbital concentrations in lipemic plasma. Microcentrifugation effectively mitigated lipemic interference and improved agreement with HPLC, supporting the use of microcentrifugation in clinical TDM workflows.

  • Evaluation of Compatibility and Stability of Compounded Otic Solutions Containing Enrofloxacin Over a 20‐Day Period

    by Shae Atterberg, Amelia White, Crisanta Cruz‐Espindola, Kamoltip Thungrat, Alex Jenkins, Zachary Lough, Dawn Boothe

    Background: Compounded otic solutions containing enrofloxacin are commonly used in the management of otitis. Hypothesis/Objectives: The study objective was to evaluate the compatibility and stability of enrofloxacin in compounded otic solutions, as determined by physical changes and quantitated strength. Materials and Methods: Twelve solutions containing 100 mg/mL enrofloxacin (Baytril 100; Elanco) or 22.7 mg/mL enrofloxacin (Baytril; Elanco) were quantitatively analysed on Day (D)0, D10, D15, and D20. Both concentrations of enrofloxacin were combined with sterile water (Hospira), tris‐EDTA (TrizEDTA; Dechra), sterile water and 4 mg/mL dexamethasone sodium phosphate (dexamethasone, Dexium‐SP; Bimeda), tris‐EDTA and dexamethasone, tris‐EDTA with 0.15% ketoconazole (TrizULTRA Keto; Dechra) and dexamethasone, and 1% miconazole nitrate lotion (Covetrus) and dexamethasone. Gross and microscopic evaluation, pH, and temperature were used to assess physical compatibility. Mass spectrometry was used to evaluate precipitate. High‐performance liquid chromatography was used to quantitate drug concentration, indicating strength. Initial separation of ingredients indicating lack of homogenous mixing, immediate precipitate formation, and an exothermic reaction deterred drug strength measurement in solutions containing an antifungal. Results: On D10, in solutions containing tris‐EDTA, average enrofloxacin concentration decreased 25.4% with 100 mg/mL enrofloxacin, 29.3% with 100 mg/mL enrofloxacin and dexamethasone, 45.6% with 22.7 mg/mL enrofloxacin, and 49.8% with 22.7 mg/mL enrofloxacin and dexamethasone. Precipitate formed in all solutions containing tris‐EDTA and filtration of the precipitate did not impact the measured enrofloxacin concentration. Compatibility and stability of enrofloxacin were verified in all solutions containing sterile water. Conclusions and Clinical Relevance: Clinical use of solutions containing enrofloxacin combined with tris‐EDTA or an antifungal is injudicious owing to incompatibility and instability.

  • Open Access

    Pharmacokinetics of intranasal levetiracetam in healthy dogs: a feasible route of administration

    by Ewa Krolak, Kamoltip Thungrat, Amanda Gross, Katherine Gerken, Kendon Kuo, Tom Jukier

    Objective: To describe the pharmacokinetics of the IV formulation of levetiracetam administered intranasally and calculate the absolute bioavailability. Our hypothesis was that levetiracetam would show near complete absorption following a single intranasal dose. Methods: 8 healthy dogs (4 female, 4 male) from a canine colony were used in a crossover study comparing the pharmacokinetics of intranasal and IV levetiracetam. The study occurred from August through September 2024. A 100-mg dose of levetiracetam was administered via the intranasal and IV routes on separate occasions. Blood was collected from jugular catheters over a 24-hour period following dose administration. Plasma levetiracetam concentrations were analyzed using high-pressure liquid chromatography. Noncompartmental analysis was performed to describe the pharmacokinetics. Results: Median (minimum to maximum), maximal concentration, time to maximal concentration, and elimination half-life for the intranasal route were 7.85 µg/mL (range, 3.37 to 14.16), 0.98 hours (range, 0.22 to 1.00), and 2.83 hours (range, 2.44 to 3.76), respectively. Median (minimum to maximum) bioavailability was 61% (range, 34% to 85%). The maximal concentration achieved fell within the human reference interval for levetiracetam in 5 of 8 dogs. Conclusions: Levetiracetam was absorbed to a moderate degree following the intranasal route of administration and appeared to be well tolerated. Clinical Relevance: Levetiracetam is absorbed via the nasal administration route and could be considered a feasible route of administration for at-home rescue protocols. Although concentrations within the human reference interval were achieved in a majority of dogs, a clinical trial is necessary to determine if this method of administration would be effective in a clinical setting.

  • Open Access

    Efficacy of monotherapy with zonisamide and proposed reference interval in dogs with epilepsy: a cohort of 207 dogs (2011-2021)

    by Kamoltip Thungrat, Tom Jukier, Dawn Merton Boothe

    Background: Zonisamide (ZNS) has become a popular antiseizure medication (ASM) to treat epilepsy in dogs. Dose adjustments based on plasma ZNS concentrations facilitate management, but efficacy evidence is limited. No reference interval (RI) is established in dogs. Hypothesis/Objectives: To assess ZNS efficacy and establish an RI for dogs with epilepsy. Animals: Two hundred seven dogs with non-structural epilepsy received ZNS monotherapy, with samples submitted for therapeutic drug monitoring (TDM). Methods: In this retrospective observational study, ZNS information was collected from the TDM data record library between November 2011 and May 2021. Exclusion criteria were structural epilepsy, receiving other ASMs, dogs’ age >6 years, or a duration of ZNS <3 months. Zonisamide response was assessed as described in the International Veterinary Epilepsy Task Force (IVETF) consensus. Plasma ZNS concentrations from responders (categories 1 [seizure freedom] and 2 [partial response]) were evaluated at the established RI. Results: Two hundred seven dogs could be assigned to IVETF response categories 1-3. The proportion of responders (59%, n = 123), including categories 1 (29%) and 2 (30%), was higher than non-responders (category 3, 41%, n = 84; P < .01). Based on the responders, an RI of 10-55 μg/mL is proposed. Conclusions and clinical importance: This study demonstrated that ZNS monotherapy is effective for treatment of non-structural epilepsy. The proposed RI, 10-55 μg/mL, is a broader range than that in human medicine, 10-40 μg/mL.

  • Comparison of 3 methods of quantification of phenobarbital in canine plasma: high-performance liquid chromatography, a point-of-care immunoassay, and the FDA-approved immunoassay analyzer

    by Kamoltip Thungrat, Ryan Gibson, Tom Jukier, Alex Jenkins, Crisanta Cruz-Espindola

    Phenobarbital is a common antiseizure medication that has a relatively narrow therapeutic window. Therapeutic drug monitoring (TDM) is a helpful tool to guide dose adjustments for phenobarbital and avoid its toxicity. We investigated the agreement among 3 methods of quantifying phenobarbital in canine plasma: high-performance liquid chromatography (HPLC), point-of-care (POC) testing, and the FDA-approved immunoassay analyzer. We randomly selected 45 plasma samples obtained by the TDM service (College of Veterinary Medicine, Auburn University, Auburn, AL, USA). Passing–Bablok regression and Lin concordance correlation coefficients (CCCs) were used to determine the agreement of the results obtained for the 3 methods; Bland–Altman plots were used for bias analysis using the results from the HPLC method as a reference. The FDA-approved immunoassay analyzer and POC immunoassay method results agreed with the HPLC. The results from the FDA-approved immunoassay analyzer were better correlated than those from the POC method, with Lin CCCs of 0.96 (95% CI: 0.93–0.98) and 0.94 (95% CI: 0.90–0.97), respectively. The average biases of the FDA-approved and the POC immunoassay analyzers were 0.80 and −0.64 µg/mL, respectively. Based on the CIs of Lin CCCs, the commercial POC phenobarbital test is a good screening tool and agrees with the HPLC method. However, the FDA-approved immunoassay analyzer method allows for more accurate quantification of phenobarbital concentrations, which is required for appropriate dose adjustment of phenobarbital.


  • Evaluation of a fluorescence resonance energy transfer quantitative polymerase chain reaction assay for identification of gyrA mutations conferring enrofloxacin resistance in canine urinary Escherichia coli isolates and canine urine specimens

    by Megan G. Behringer, Dawn M. Boothe, Kamoltip Thungrat

    OBJECTIVE To evaluate a fluorescence resonance energy transfer quantitative PCR (FRET-qPCR) assay for detection of gyrA mutations conferring fluoroquinolone resistance in canine urinary Escherichia coli isolates and canine urine specimens. SAMPLE 264 canine urinary E coli isolates and 283 clinical canine urine specimens. PROCEDURES The E coli isolates were used to validate the FRET-qPCR assay. Urine specimens were evaluated by bacterial culture and identification, isolate enrofloxacin susceptibility testing, and FRET-qPCR assay. Sensitivity and specificity of the FRET-qPCR assay for detection of gyrA mutations in urine specimens and in E coli isolated from urine specimens were computed, with results of enrofloxacin susceptibility testing used as the reference standard. RESULTS The validated FRET-qPCR assay discriminated between enrofloxacin-resistant and enrofloxacin-susceptible E coli isolates with an area under the receiver operating characteristic curve of 0.92. The assay accurately identified 25 of 40 urine specimens as containing enrofloxacin-resistant isolates (sensitivity, 62.5%) and 226 of 243 urine specimens as containing enrofloxacin-susceptible isolates (specificity, 93.0%). When the same assay was performed on E coli isolates recovered from these specimens, sensitivity (77.8%) and specificity (94.8%) increased. Moderate agreement was achieved between results of the FRET-qPCR assay and enrofloxacin susceptibility testing for E coli isolates recovered from urine specimens. CONCLUSIONS AND CLINICAL RELEVANCE The FRET-qPCR assay was able to rapidly distinguish between enrofloxacin-resistant and enrofloxacin-susceptible E coli in canine clinical urine specimens through detection of gyrA mutations. Therefore, the assay may be useful in clinical settings to screen such specimens for enrofloxacin-resistant E coli to avoid inappropriate use of enrofloxacin and contributing to antimicrobial resistance.

  • In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates

    by Xiaoqiang Liu, Caterina Lazzaroni, Sherine A. Aly, Kamoltip Thungrat, Dawn M. Boothe